YEXT:NYSEYext, Inc. Analysis
Data as of 2026-08-01 - not real-time
$5.46
Latest Price
7/10Risk
Risk Level: Medium
Executive Summary
Yext’s stock trades at $5.46, which sits above its DCF‑derived fair value of $2.41, indicating a significant overvaluation (DCF upside/downside -8.4%). The company’s valuation multiples are stretched, with a trailing P/E of 68.25 versus an industry average of 32.8, while the forward P/E collapses to 8.27, reflecting a market expectation of sharply higher earnings. Technicals show the price above the 20‑day SMA (5.27) and 50‑day SMA (4.56), but the MACD histogram is negative and the signal line is bearish, and the RSI at 60.6 suggests limited upside momentum. Fundamentals reveal strong profitability – gross margin near 75% and operating margin 11.4% – and an exceptional ROE of 47.7%, yet revenue is contracting (‑1.4% YoY) and the balance sheet is weak, with a debt‑to‑equity ratio near 918. Recent Q1 results missed revenue expectations, sending the stock down 11.9% in after‑hours trading, underscoring short‑term pressure.
Given the high volatility (55% 30‑day) and decreasing volume, combined with a low beta, the stock faces moderate market risk, while its heavy leverage and lack of dividend further temper long‑term appeal. Investors should weigh the strong margins and forward earnings upside against the overvaluation and balance‑sheet strain when deciding on exposure.
Given the high volatility (55% 30‑day) and decreasing volume, combined with a low beta, the stock faces moderate market risk, while its heavy leverage and lack of dividend further temper long‑term appeal. Investors should weigh the strong margins and forward earnings upside against the overvaluation and balance‑sheet strain when deciding on exposure.
Market Outlook
Short Term
< 1 yearCautious
Model confidence: 6/10
Key Factors
- Q1 revenue miss and 11.9% after‑hours price drop
- Bearish MACD signal and neutral trend direction
- Current price well above DCF fair value
Medium Term
1–3 yearsNeutral
Model confidence: 5/10
Key Factors
- Forward P/E of 8.27 suggests earnings improvement
- High gross margin and ROE indicate operational strength
- Elevated debt‑to‑equity ratio remains a downside risk
Long Term
> 3 yearsNeutral
Model confidence: 4/10
Key Factors
- Sustainable high‑margin SaaS business model
- Absence of dividend and ongoing leverage concerns
- Sector volatility and overvaluation relative to fundamentals
Key Metrics & Analysis
Financial Health
Revenue Growth-1.40%
Profit Margin8.93%
P/E Ratio68.3
ROE47.72%
ROA0.72%
Debt/Equity917.94
P/B Ratio4.2
Op. Cash Flow$55.6M
Free Cash Flow$29.2M
Industry P/E32.8
Technical Analysis
TrendNeutral
RSI60.6
Support$4.75
Resistance$5.80
MA 20$5.27
MA 50$4.56
MA 200$5.93
MACDBearish
VolumeDecreasing
Fear & Greed Index92.88
Valuation
Fair Value$2.41
Target Price$5.00
Upside/Downside-8.42%
GradeOvervalued
TypeBlend
Risk Assessment
Beta0.69
Volatility55.58%
Sector RiskMedium
Reg. RiskLow
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.